PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE
19 juin 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, June 19, 2018 (GLOBE NEWSWIRE) -- Provectus today announced that the Indian Patent Office (IPO) has granted the Company’s patent application for the synthetic...
How to Use Stick and Spray Sunscreens; American Academy of Dermatology
12 juin 2018 14h00 HE
|
American Academy of Dermatology
ROSEMONT, Ill., June 12, 2018 (GLOBE NEWSWIRE) -- Sunscreen is a vital tool in the fight against skin cancer, including melanoma, the deadliest form. Research suggests that daily sunscreen use —...
American Academy of Dermatology PSA Highlights Dangers of Tanning
22 mai 2018 10h30 HE
|
American Academy of Dermatology
ROSEMONT, Ill., May 22, 2018 (GLOBE NEWSWIRE) -- As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside — and some may want...
Research Shows Increased Skin Cancer Risk Among U.S. Military Members
17 mai 2018 16h14 HE
|
American Academy of Dermatology
ROSEMONT, Ill., May 17, 2018 (GLOBE NEWSWIRE) -- When one considers the risks of military service, skin cancer may not be top of mind. According to research published in the Journal of the American...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
24 avr. 2018 07h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
19 avr. 2018 06h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
13 nov. 2017 08h30 HE
|
Galectin Therapeutics Inc.; Providence Cancer Institute
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today...
PROVECTUS BIOPHARMACEUTICALS RECEIVES SECOND CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE
07 nov. 2017 16h00 HE
|
Provectus Biopharmaceuticals Inc.
– Protection expands coverage for combinations of intralesional PV-10 with anti-PD-1 and anti-PD-L1 agents for melanoma and cancers of the liver – KNOXVILLE, TN, Nov. 07, 2017 (GLOBE NEWSWIRE)...
Pet Cancer Therapeutics Market worth over $300 million by 2024: Global Market Insights, Inc.
09 août 2017 06h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, Aug. 09, 2017 (GLOBE NEWSWIRE) -- The Industry Analysis report “Pet Cancer Therapeutics Market By Medicine Type (Chemotherapy Drugs and Vaccines), By Species (Dogs and Cats),...
Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
23 févr. 2017 09h00 HE
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in...